Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Enoxacin ocular sustained release gelata and preparation thereof

A slow-release gel, plus enoxacin technology, applied in the field of medicine, can solve the problems of patients who are not willing to use, low bioavailability, strong greasy feeling, etc., to maintain effective drug concentration, long residence time, The effect that is not easy to lose

Inactive Publication Date: 2009-12-02
SHENYANG PHARMA UNIVERSITY
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Eye drops are the most commonly used dosage form in ophthalmology. After administration, they are diluted to 0.1% of the original concentration by tears within a few minutes, and the bioavailability is low, only 1%-10%. Therefore, the frequency of eye drops needs to be increased, and it is inconvenient for patients to use. Poor compliance and may cause systemic toxicity
Although the release of eye ointment is slow, patients are not willing to use it because of its strong greasy feeling and easy to cause "blurred vision" due to the base of Vaseline

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Take 39kg of deionized water, add 0.15kg of enoxacin, stir to dissolve. Take 2kg of sodium alginate and sprinkle it into the above solution. Let stand overnight, then add 0.001 kg of benzalkonium bromide and 0.4 kg of sodium chloride, and stir to dissolve. Use 10% NaOH solution to adjust the pH to 7.4, dissolve and pass through a 0.22um microporous membrane, and add water from the filter to a total of 50kg. Sampling is carried out for quality identification, and after passing the test, it is subpackaged in eye drop bottles under a sterile environment, and then packaged to obtain the product.

Embodiment 2

[0028] Take 39kg of deionized water, add 0.15kg of enoxacin, stir to dissolve. Take 1.5 kg of hydroxypropyl methylcellulose (HPMC F4M) and sprinkle it into the above solution. Let stand overnight, then add 0.001 kg of benzalkonium bromide and 0.4 kg of sodium chloride, and stir to dissolve. Adjust the pH to 7 with boric acid, dissolve and pass through a 0.22um microporous membrane, and add water from the filter to a total of 50kg. Sampling is carried out for quality identification, and after passing the test, it is subpackaged in eye drop bottles under a sterile environment, and then packaged to obtain the product.

Embodiment 3

[0030] Take 39kg of deionized water, add 0.15kg of enoxacin, stir to dissolve. Take 2kg of methylcellulose and sprinkle it into the above solution. Let stand overnight, then add 0.001 kg of benzalkonium bromide and 0.4 kg of sodium chloride, and stir to dissolve. Use 10% NaOH solution to adjust the pH to 7, dissolve and pass through a 0.22um microporous filter membrane, and add water from the filter to a total of 50kg. Sampling is carried out for quality identification, and after passing the test, it is subpackaged in eye drop bottles under a sterile environment, and then packaged to obtain the product.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an enoxacin ophthalmic sustained-release gel and a preparation method thereof, which has the characteristics of maintaining effective drug concentration for a long time and good compatibility. It is composed of the following components: component content (weight%) enoxacin 0.1-1, thickener 0.1-40, preservative 0.001-3, isotonic regulator 0.1-10, pH regulator to adjust the pH value The amount is 4.5-9, the balance of water. It is to dissolve enoxacin in water, add a thickener and let it stand overnight, then add preservatives and isotonic regulators, stir to dissolve, adjust the pH to 4.5-9 with a pH regulator, and pass the solution through a microporous membrane It is prepared by filtering and adding water from the filter to the total amount. This ophthalmic preparation is suitable for treating bacterial conjunctivitis, keratitis and other eye infections.

Description

Technical field: [0001] The invention relates to the technical field of medicine, in particular to an enoxacin ophthalmic sustained-release gel and a preparation method thereof. Background technique: [0002] According to statistics, more than 80% of the patients who go to see a doctor in ophthalmology are ocular infections. Ophthalmic infections include conjunctivitis, keratitis, and global inflammation; divided from pathogenic bacteria, including bacterial infections and fungal infections. Anti-infective drugs can be used for bacterial infection, but due to the existence of the blood-ocular barrier, the drugs cannot fully penetrate into the eye, and the drug concentration in the intraocular tissue is low. Therefore, the anti-infective drugs used in ophthalmology are those with good permeability, such as tobramycin, cleomycin and chloramphenicol. In recent years, the application of quinolones in ophthalmology has grown rapidly, such as ofloxacin, levofloxacin, norfloxacin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/496A61K9/00A61P27/02A61P31/04A61P31/10
Inventor 潘卫三刘志东王思玲
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com